You are here

Genetics of Chemotherapy-Related Amenorrhea Study

Researcher
Kathryn Ruddy, MD, and Celine Vachon, PhD, Mayo Clinic, Rochester, Minnesota
Study abstract

Chemotherapy for breast cancer can damage the ovaries and cause infertility and menopausal symptoms. Learning more about genetic predictors of chemotherapy-related amenorrhea (a surrogate for treatment-related infertility) could help inform decision-making about breast cancer treatments. This study aims to survey breast cancer survivors about how chemotherapy affected their menstrual periods, and to collect saliva samples in which we can look for genetic variants that are associated with a greater risk of early menopause. The research team will also be asking for permission to collect and review medical records to obtain detailed treatment information for these analyses.

Study review

The purpose of this study was to identify genes that may contribute to the effect that chemotherapy has on a woman’s ovaries. The researchers wanted to enroll up to 5,000 volunteers from the Army of Women (AOW) from anywhere in the U.S. The Call to Action for this study was sent to AOW members on December 16, 2015. The researchers closed enrollment on March 14, 2017, after the AOW provided them with 882 women who were interested in enrolling in the study.